News

Smartkem's 2024 Successes and Ambitious Plans for 2025

Smartkem's 2024 Successes and Ambitious Plans for 2025

Smartkem's Remarkable Journey Through 2024

Smartkem, a leader in innovative organic thin-film transistors (OTFTs), has highlighted its significant accomplishments from the past year and set ambitious targets for 2025. With a commitment to transforming the electronics industry, Smartkem's journey in 2024 was marked by noteworthy achievements and strategic partnerships.

Achievements of 2024

The year 2024 proved to be transformational for Smartkem as they secured funding and forged crucial collaborations. One of the standout moments was their successful fundraising effort, raising $7.65 million, which will further support the development of their innovative technologies. A significant milestone included receiving a $1.1 million grant for a collaborative project aimed at creating the world's first rollable and transparent microLED display.

Smartkem's upward trajectory continued with their uplisting to Nasdaq, a strategic move that enhanced trading liquidity and broadened their reach to a wider array of investors. This change positions the company well within the rapidly growing microLED industry, projected to expand from $150 million in 2024 to over $4 billion by 2031.

Partnerships and Collaborations

In 2024, Smartkem entered into multiple strategic partnerships with leading display manufacturers across continents. Collaborations included an agreement with AUO to develop an advanced rollable transparent microLED display and a partnership with FlexiIC to create rapid turnaround custom circuits utilizing organic transistor technology.

Furthermore, valuable partnerships included working with the Industrial Technology Research Institute (ITRI) for product prototyping and with the Chip Foundation on developing new microLED-based technologies. Notable is their collaboration with Tianma Microelectronics, focusing on OTFT-based microarray biochips.

Research and Development Goals for 2025

Looking ahead, Smartkem has laid out exciting goals for 2025. Key objectives include the shipment of materials to the Chip Foundation to support the ongoing microLED backlight technology projects. They plan to sign a Joint Development Agreement (JDA) aimed at a chip-first microLED display, which showcases their commitment to advancing display technologies.

Advancing Technology and Market Expansion

Smartkem aims to complete critical qualifications for their Gen 2.5 ITRI process line, which will enhance their production capabilities. Additionally, the company plans to enter into more collaborations and co-development agreements that will pave the way for their technology's commercialization.

All these initiatives signify a robust outlook as Smartkem strives to solidify its position at the forefront of the evolving electronics market. The CEO, Ian Jenks, emphasized gratitude towards their stockholders, highlighting the company's commitment to keeping them updated on progress through the year.

About Smartkem

Smartkem focuses on revolutionizing the electronics sector through its groundbreaking work with organic thin-film transistors. Their innovative TRUFLEX® liquid semiconductor polymers facilitate the creation of transistors applicable in various display technologies, including next-generation microLEDs. Equipped with a rich intellectual property portfolio comprising 138 granted patents and 40 trade secrets, Smartkem continues its mission to enhance display technologies, delivering high-performance solutions that meet contemporary demands.

The company operates its research and development facility in Manchester, UK, while providing extensive prototyping services in Sedgefield, UK and maintaining a field application office in Taiwan. Their initiatives and breakthroughs are poised to make a significant impact on various sectors reliant on advanced display technologies.

Frequently Asked Questions

What is Smartkem known for?

Smartkem is known for developing innovative organic thin-film transistors (OTFTs) aimed at revolutionizing display technologies, particularly in the microLED sector.

What were Smartkem's major achievements in 2024?

The major achievements included raising $7.65 million in funding, receiving a significant grant, uplisting to Nasdaq, and forming strategic partnerships for developing advanced display technologies.

What are Smartkem's goals for 2025?

Smartkem aims to ship materials for microLED development, finalize a Joint Development Agreement for a new display, and enhance technological qualifications, among other objectives.

How many patents does Smartkem hold?

Smartkem holds an impressive portfolio featuring 138 granted patents across 18 patent families and 40 codified trade secrets, underscoring their competitive edge in the industry.

Where is Smartkem's headquarters located?

Smartkem's headquarters are in Manchester, UK, where it also conducts extensive research and development to push the boundaries of display technology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 136

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 80

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 53

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 208

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 206

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 68

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 153

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 17

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 277

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 287

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Elections: How EP3 Technology Transformed Voting

Updated Category News Views 114

EP3 Technology Powers Transformative Election Insights ForecastEx, a dynamic subsidiary of Interactive Brokers (IBKR), achieved a remarkable feat by processing over $560 million in election contracts during the 2024 U.S. general election. The groundbreaking technology enabling this achievement is Connamara Technologies' EP3 matching engine, an innovative platform designed...

Continue Reading
GI Partners and Legacy Investing Transform Chicago Landmark

Updated Category News Views 269

Transforming a Chicago Landmark into a Modern Data Center The historic 300,500 square foot building located at 400 S. LaSalle Street, once the home of the Chicago Board Options Exchange, is set to undergo an exciting transformation. Through an acquisition announced recently, GI Partners and Legacy Investing, LLC have acquired this prominent property with the intention of...

Continue Reading
Radiotherapy Market to Hit $10.68B in 2031, Growth Ahead

Updated Category News Views 30

Radiotherapy Market's Projected Growth: What's Fueling It? It's no secret: the radiotherapy market is on an upward trajectory, heading toward a substantial $10.68 billion valuation by 2031. But what’s pushing this rocket? For starters, we’re looking at a steady compound annual growth rate (CAGR) of 6.0% from 2026 to 2031. Not too shabby in today’s volatile economic...

Continue Reading
Join the Class Action Against Newmont Corporation by April 2025

Updated Category News Views 254

Take Action: Class Action Against Newmont Corporation Levi & Korsinsky, LLP is reaching out to investors linked to Newmont Corporation, urging them to act before the April 1, 2025 deadline for joining a class action lawsuit. This lawsuit addresses alleged securities fraud that negatively impacted many of Newmont's investors. Understanding the Class Action The class action...

Continue Reading
InflaRx Unveils Promising Preclinical Findings for INF904

Updated Category News Views 76

InflaRx Unveils New Developments for INF904 InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company recognized for its innovative anti-inflammatory therapies targeting the complement system, has recently shared promising preclinical results for its oral C5aR inhibitor, INF904. This announcement took place at the 2024 European Meeting on Complement in Human Diseases...

Continue Reading